Underwood Capital Limited has released a press release.
Satipharm Gelpell Outperforms Sativex in Phase 1 Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Underwood Capital Limited on 6ix
Story so far
Earlier from Underwood Capital
- Capital Raising
- Cannabis Legalisation Gives MMJ the Green Light
- Successful Results of Phase 1 Clinical Trial
- Extension of Yissum Licensing Agreement
Later from Underwood Capital
- Progress on MMJs Lucky Lake Facility MMPR Application
- MMJ Marks AUS Market Entry with Two Strategic Partnerships
- Health Canada Grants MMJ License to Produce Medical Cannabis
- Canada Takes Steps Towards Recreational Legalisation
- MMJ Enters Strategic Land Package Agreement
Follow Underwood Capital into a list and get an email when it puts out news.
Follow Underwood Capital